Drug intelligence / Profile preview

Univ. of Bern JAK1 compound (S,R,R)-40a

Development stage: Unknown
Lead developer: University of Bern

Overview

Univ. of Bern JAK1 compound (S,R,R)-40a: sourced facts only. name: "Notably, compound (S,R,R)-40a emerged as a potent JAK1 inhibitor (IC50 = 18 nM), with similar potency as the FDA-approved inhibitors abrocitinib and upadacitinib." [PMID:41355865]; target: "Notably, compound (S,R,R)-40a emerged as a potent JAK1 inhibitor (IC50 = 18 nM), with similar potency as the FDA-approved inhibitors abrocitinib and upadacitinib." [PMID:41355865]; developer: "Department of Chemistry, Biochemistry and Pharmaceutical Sciences, University of Bern Freiestrasse 3 Bern CH-3012 Switzerland [email protected]." [PMID:41355865]

Targets

JAK1 (Janus kinase 1)

Beyond the preview

Go deeper on Univ. of Bern JAK1 compound (S,R,R)-40a.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Univ. of Bern JAK1 compound (S,R,R)-40a.